Artivion (NYSE:AORT) SVP Sells $82,997.66 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 2,183 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $38.02, for a total transaction of $82,997.66. Following the completion of the sale, the senior vice president owned 170,105 shares of the company’s stock, valued at approximately $6,467,392.10. The trade was a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Artivion Stock Performance

Shares of NYSE:AORT opened at $37.87 on Friday. The firm has a market capitalization of $1.81 billion, a PE ratio of 189.36 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The business has a 50-day moving average of $41.24 and a two-hundred day moving average of $42.88.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. The business’s revenue was up 19.2% compared to the same quarter last year. As a group, research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AORT. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Citizens Jmp lifted their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Canaccord Genuity Group reduced their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Finally, Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Artivion has an average rating of “Moderate Buy” and a consensus price target of $50.47.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Quarterly results beat expectations (EPS and revenue) and showed ~19% YoY revenue growth, supporting the growth narrative and analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference — a near‑term event where guidance, commercialization updates or product milestones could be disclosed and re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with elevated price targets), which helps sentiment but may already be priced in. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite — useful narrative fuel but not an immediate catalyst. Kalkine – Portfolio Expansion Article
• Negative Sentiment: Clustered insider selling March 2–4: CEO James Mackin sold 17,887 shares (~$676k), EVP Lance Berry sold ~6,316 shares (~$238k), other senior execs (SVPs, CAO Amy Horton and others) sold multiple tranches. Markets often interpret concentrated senior‑level sales as a negative near‑term signal despite insiders retaining large stakes. See filings and coverage. SEC Form 4 – Mackin Benzinga – CCO Trade Benzinga – Lance Berry Sale

Institutional Trading of Artivion

Several large investors have recently added to or reduced their stakes in AORT. Vanguard Group Inc. grew its position in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after buying an additional 141,030 shares during the last quarter. Morgan Stanley lifted its stake in Artivion by 0.8% during the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after buying an additional 18,248 shares in the last quarter. State Street Corp lifted its position in Artivion by 2.9% in the 4th quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after buying an additional 44,641 shares in the last quarter. Fred Alger Management LLC raised its stake in shares of Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after buying an additional 748,119 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.